Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response

The Journal of Pharmacy and Pharmacology
Rebekah BernardPeter J Little

Abstract

Tyrosine kinase inhibitors were the first class of smart drugs being specifically designed to inhibit a disease causing target. There is a very important but unresolved question as whether or not the overall therapeutic role of an individual tinib results from an action at its primary target, a single most likely, tyrosine kinase, or from the combined or aggregate action at the multiple targets which each tinib addresses. We selected a series of ten tinibs (gefitinib, sunitinib, lapatinib, erlotinib, imatinib, sorafenib, axitinib, vanitinib, bosutinib, dasatinib) with various known targets and investigated their activities in the inhibition of proteoglycan synthesis and GAG hyperelongation stimulated by a tyrosine kinase receptor agonist, platelet derived growth factor (PDGF) and for contrast, a serine/threonine kinase receptor agonist, TGF β and some downstream signalling pathways. The inhibitory activity varied from little to total inhibition. The actions of the tinibs were directed more towards inhibition of the tyrosine kinase, PDGF receptor signalling pathway compared to the TGF β. There was no suggestion of any synergistic effect arising from inhibition of multiple kinases as the most potent compound, dasatinib, is known ...Continue Reading

References

Mar 12, 1990·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·R RossE W Raines
Jul 25, 1998·Genes & Development·Y G ChenJ Massagué
Oct 6, 1998·Annual Review of Biochemistry·J Massagué
Oct 30, 2001·Annals of Medicine·H Joensuu, S Dimitrijevic
Jun 28, 2002·Cancer Cell·Laura K ShawverAxel Ullrich
Jul 18, 2002·Nature Reviews. Drug Discovery·Renaud CapdevilleAlex Matter
May 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiro FukuokaJosé Baselga
Feb 26, 2004·Blood·Bruno Calabretta, Danilo Perrotti
Jan 5, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Shinong WangRaimund Hirschberg
Mar 15, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Entong WangMin Zhao
Jul 9, 2005·The Journal of Pharmacology and Experimental Therapeutics·Amit Arora, Eric M Scholar
Feb 24, 2006·Endocrine Reviews·Julie NigroPeter J Little
Dec 1, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Robert HägerkvistNils Welsh
Feb 17, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Yutaka NakashimaKatsuo Sueishi
Sep 27, 2007·Nature Reviews. Molecular Cell Biology·Peter ten Dijke, Helen M Arthur
Jan 29, 2008·The Journal of Biological Chemistry·Harsha DadlaniPeter J Little
Nov 19, 2008·Proceedings of the National Academy of Sciences of the United States of America·Cédric LouvetJeffrey A Bluestone
Dec 17, 2008·Cardiovascular & Hematological Disorders Drug Targets·Narin OsmanPeter J Little
Jul 8, 2009·Archives of Physiology and Biochemistry·Sundy N Y YangPeter J Little
Aug 20, 2009·Current Drug Metabolism·Jörg Thomas HartmannHans-Peter Lipp
Sep 17, 2009·Journal of Cellular and Molecular Medicine·Mandy L BallingerPeter J Little
Mar 10, 2010·Cellular and Molecular Life Sciences : CMLS·Micah L BurchPeter J Little
Aug 6, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Nicole M AgostinoJoseph J Drabick
Sep 8, 2010·Cellular and Molecular Life Sciences : CMLS·Micah L BurchPeter J Little
Nov 27, 2010·Journal of Hematology & Oncology·Guoqing WeiDelong Liu
Sep 3, 2011·Clinical and Experimental Pharmacology & Physiology·Hossein B RezaeiPeter J Little
Jan 3, 2013·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Daisuke KitagawaYasuyuki Kirii
Apr 24, 2013·Therapeutic Advances in Hematology·Pavan Kumar BhamidipatiElias Jabbour
May 11, 2013·Pulmonary Circulation·Nicholas W MorrellKurt R Stenmark
Aug 15, 2013·Chemistry : a European Journal·Moom Sinn AwDusan Losic

❮ Previous
Next ❯

Citations

Feb 14, 2018·The Journal of Pharmacology and Experimental Therapeutics·Muhamad A RostamPeter J Little
Feb 9, 2017·Journal of Cell Communication and Signaling·Rebecca ChaplinDanielle Kamato
Jan 11, 2021·Translational Research : the Journal of Laboratory and Clinical Medicine·Fabian A MendozaSergio A Jimenez
Jun 23, 2020·ACS Pharmacology & Translational Science·Rizwana AfrozDanielle Kamato

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.